Neurotoxicity risk assessment of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) as a synthetic impurity of drugs

Abstract

1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) induces symptoms indistinguishable from those of Parkinson's disease. It selectively destroys dopaminergic neurons in the substantia nigra and the globus pallidus. Death of these same neurons is apparently the cause of idiopathic Parkinson's disease. As phenyl-1,2,3,6 tetrahydropyridine is a commonly encountered subunit in heterocyclic drugs and because MPTP was found as a minor impurity in early batches of a candidate drug at Merck KGaA, it may be assumed that MPTP will also be present as an as yet undiscovered minor impurity in various existing drugs. A neurotoxicity risk assessment on MPTP has been conducted to define the risk of MPTP as an impurity in drugs that are used orally. This risk assessment has shown that compounds containing less than 5.0 p.p.m. MPTP administered orally will not cause a neurotoxicological health risk to patients treated with such a drug.

Keywords

risk assessment N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine impurity drugs pesticides neurotoxicity

Get full access to this article

View all access options for this article.

References

Johannessen JN. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4- phenylpyridinium (MPP+) within catecholaminergic neurons . Neuro toxicology 1991; 12: 285-302 .

Schneider JS. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys . Brain Research 1990; 534: 25-36 .

Schneider JS , Kovelowski CJ. Chronic exposure to low doses of MPTP . Cognitive deficits in motor asymptomatic monkeys. Brain Research 1990; 519: 122-128 .

Advances in Neurology 1990; 53: 239-244 , Raven Press, NY .

Irvin et al. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey . Brain Research 1990; 531: 242-252 .

Russ H et al. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset; implications for Parkinson's disease ? Neuroscience Letters 1991; 123: 115-118 .

Fuller RW , Hemrick-Luecke SK and Perry KW. Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice . Life Sciences 1989; 45: 2077-2083 .

Fuller RW , Hemrick-Luecke SK. Tissue concentration of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice . Toxicology Letters 1990; 54: 253-262 .

Fuller RW , Hemrick-Luecke SK. Oral versus parenteral efficacy of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): Differential effects on depletion of heart norepinephrine and of striatal dopamine in mice . Biochemical Pharmacology 1987; 36: 789-792 .

10.

Haeusler G et al. Review of MPTP in the chemical, pharmacological, toxicological and clinical development of EMD 49 980. Merck KGaA, Darmstadt, 1993 (unpublished report).

11.

Rose S et al. Age-related effects of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets . European Journal of Pharmacology 1993; 230: 177-185 .

12.

Zuehlke U, Buehring KU. EMD 46 311 (MPTP)/ EMD 49 980 (Roxindol) Bioavailability after oral administration of low doses to cynomolgus monkeys. Merck KGaA, Darmstadt, 1995 (unpublished report).

13.

Roeltgen DP , Schneider JS. Chronic low-dose MPTP in nonhuman primates. A possible model for attention deficit disorder . Journal of Child Neurology 1991; 6: 82-89 .

14.

Hantraye P et al. Stable Parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons . Neuroscience 1993; 53: 169-178 .

15.

Perez-Otano et al. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset . Brain Research 1991; 567: 127-132 .

16.

Tempel P, Zuehlke U, Weisse C et al. EMD 49-980-14 day intravenous subacute study in the Cynomolgus monkey. Merck KGaA, Darmstadt, 1994 (unpublished report).

17.

Kramer PJ. MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine). Toxicological statement on the results of a literature review on oral toxicity and threshold doses for the neurotoxic effect of MPTP. Merck KGaA, Darmstadt, 1993 (unpublished report).

18.

Bachurin SO , Tkachenko SE , Lermontova NN. Pyridine derivatives: structure-activity relationships causing Parkinsonian-like symptoms . Rev Environ Contam Toxicol 1991; 122: 1-36 .

19.

Perry TL , Jones JK , Hansen S , Wall RA. 2- Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease . Journal of the Neurological Sciences 1988; 85: 309-317 .

20.

Zuber M , Alperovitch A. Maladie de Parkinson et facteurs environnementaux . Rev. Epidèm. et Santé Publ. 1991; 39: 373-387 .

21.

Feige K. Determination of MPTP in EMD 49980 lot 50862. Merck KGaA, Darmstadt, 1994 (unpublished report).

22.

Neumann W. 13-week toxicity of EMD 49 980 in Cynomolgus monkeys by oral administration. Merck KGaA, Darmstadt, 1987 (unpublished report).

23.

Neumann W. 13-week toxicity of EMD 49 980 in Cynomolgus monkeys by oral administration. Merck KGaA, Darmstadt, 1986 (unpublished report).

24.

Kovac W. Peer review of the brain histopathology of 30 monkeys of the following study. 13-week toxicity of EMD 49 980 in Cynomolgus monkeys of the following study: 13-week toxicity of EMD 49 980 in Cynomolgus monkeys by oral administration. Project No 1 2736.87, 1992 (unpublished report).

25.

Tempel P et al. EMD 49 980-90 day oral (gavage) subchronic toxicity study in the Cynomolgus monkey. Merck KGaA, Darmstadt, 1993 (unpublished report).

26.

Bühring KU et al. Determination of 1-methyl-4- phenylpyridinium (MPP+) in plasma, tissues and urine of monkeys after repeated iv and po administration of the neurotoxin 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) by HPLC with fluorometric detection . J Chromatog 1997 (in press).

27.

Weller RO. Neurotoxicity of EMD 49 980 Examination of historical material from monkey brains to ensure the absence of MPTP-like neurotoxicity in EMD 49 980-treated animals. Southampton General Hospital UK 1993 (unpublished report).

28.

Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes . J Neuroimmunol 1985; 8: 203-214 .

29.

Norton WT et al. Quantitative aspects of reactive gliosis: A review . Neurochem Res 1992; 17: 877-885 .

30.

Montgomery DL. Astrocytes: Form, functions and roles in disease . Vet. Pathol. 1994; 31: 145-167 .

31.

O'Callaghan JP , Miller DB , Reinhard Jr. JF. Characterization of the origins of astrocytes response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine . Brain Res 1990; 521: 73-80 .

32.

Tempel P, Hofmann A. EMD 49 980-52 week oral (gavage) chronic toxicity study in the Cynomolgus monkey with an 8-week treatment-free period. Report HLD 70/11; 40107/90. Merck KGgA, Darmstadt, 1990 (unpublished report).

33.

Coleman J et al. 1-Methyl-4-phenyl-1,2,3,6- tetrahydro-pyridine is N-demethylated by Cytochrome P450 2D6, 1A2 and 3A4-Implications for susceptibility to Parkinson's disease . Pharmacol. Exp. Ther. 1996: 277, 685-685 .